A Phase 3 interventional study of Pembrolizumab and Lenvatinib in Endometrial Neoplasms, sponsored by Eisai Inc.. Completed at 169 sites in 21 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing pembrolizumab in Endometrial Neoplasms — 5 open to participants now, 12 under way, 5 of them phase 3. pembrolizumab · Endometrial Neoplasms.
Among the 25 studies testing pembrolizumab in Endometrial Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2018, is one of 8 in phase 3, and was the 10th registered.
1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.
Browse Endometrial Neoplasms studies →5 of the 25 studies testing pembrolizumab in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+ · Women only
National Cancer Institute (NCI) · Sites in United States
Ages 18+ · Women only
Peking University People's Hospital · Sites in China
Ages 18–45 · Women only
National Cancer Institute (NCI) · Sites in United States
Ages 18–72
By country, each count listing its studies:
pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, pembrolizumab is the treatment under test here. Read study by study →
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 11 · Phase 3 8
First in 2010; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 827 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 46 across the 25 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 6 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing pembrolizumab in Endometrial Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04634877Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | 2026-11-20 |
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT02628067Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | 2027-05-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies testing pembrolizumab in Endometrial Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has radiographic evidence of disease progression after 1 prior systemic, platinum-based chemotherapy regimen for EC. Participants may have received up to 1 additional line of platinum-based chemotherapy if given in the or adjuvant treatment setting.
Note: There is no restriction regarding prior hormonal therapy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
Drug: Pembrolizumab · Drug: Lenvatinib
Participants will receive either of the following treatments: doxorubicin 60 milligram per square meter (mg/m\^2) administered by IV on Day 1 of each 21-day cycle for up to a maximum cumulative dose of 500 mg/m\^2 OR paclitaxel 80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
Drug: Paclitaxel · Drug: Doxorubicin
200 mg administered by IV infusion on Day 1 of each 21-day cycle.
Also known as: KEYTRUDA®, MK-3475
20 mg administered orally (PO) QD during each 21-day cycle.
Also known as: LENVIMA®
80 mg/m\^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
Also known as: TAXOL®
60 mg/m\^2 administered by IV on Day 1 of each 21-day cycle.
Also known as: ADRIAMYCIN®
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants
PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression, as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.
Time frame: Up to approximately 27 months
PFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants
PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression, as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.
Time frame: Up to approximately 27 months
Overall Survival (OS) in pMMR Participants
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the date of data cut-off were censored at the date the participant was last known alive, or date of data cut-off, whichever occurred first.
Time frame: Up to approximately 43 months
OS in All-comer Participants
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the date of data cut-off were censored at the date the participant was last known alive, or date of data cut-off, whichever occurred first.
Time frame: Up to approximately 43 months
Objective Response Rate (ORR) in pMMR Participants
ORR was defined as the percentage of participants who had best overall response of either complete response (CR) or partial response (PR) as determined by BICR per RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Up to approximately 80 months
ORR in All-comer Participants
ORR was defined as the percentage of participants who had best overall response of either complete response (CR) or partial response (PR) as determined by BICR per RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Up to approximately 80 months
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in pMMR Participants
EORTC QLQ-C30 was a questionnaire which included 30 questions that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.
Time frame: Baseline, Week 12
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in All-comer Participants
EORTC QLQ-C30 was a questionnaire which included 30 questions that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.
Time frame: Baseline, Week 12
Number of Partricipants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs)
TEAEs were AEs that occurred (or worsened, if present at baseline) after the first dose of study drug through 28 days after the last dose. An AE was any untoward medical occurrence in a participant temporally associated with use of study treatment, whether or not related to the treatment. An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly/birth defect. An irAE was any unfavorable and unintended immune-related sign, symptom, or disease (new or worsening) temporally associated with study therapy, regardless of whether a causal relationship with the therapy could be determined.
Time frame: Up to approximately 77 months
Number of Participants Who Discontinued Study Treatment Due to a TEAE in pMMR Participants
TEAEs was defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: Up to approximately 77 months
Number of Participants Who Discontinued Study Treatment Due to a TEAE in All-comer Participants
TEAEs was defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Time frame: Up to approximately 77 months
Time to Treatment Failure Due to Toxicity in pMMR Participants
Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date a participant discontinued study treatment due to TEAEs.
Time frame: Up to approximately 77 months
Time to Treatment Failure Due to Toxicity in All-comer Participants
Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date a participant discontinued study treatment due to TEAEs.
Time frame: Up to approximately 77 months
Plasma Concentration of Lenvatinib Versus Time in All-comer Participants
Pharmacokinetic (PK) samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted plasma concentration of lenvatinib was then derived from the PK model.
Time frame: Cycle 1 day 1 0.5-4 hours (h), 6-10 postdose; Cycle 1 day 15 predose; Cycle 1 day 15 2-12h postdose, Cycle 2 day 1 predose, 0.5-4h, 6-10 h (Each cycle is 21 days)
Plasma Concentration of Lenvatinib Versus Time in pMMR Participants
PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted plasma concentration of lenvatinib was then derived from the PK model.
Time frame: Cycle 1 day 1 0.5-4 hour (h), 6-10 postdose; Cycle 1 day 15 predose; Cycle 1 day 15 2-12h postdose, Cycle 2 day 1 predose, 0.5-4h, 6-10 h (Each cycle is 21 days)
Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib
Sparse pharmacokinetic (PK) samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted CL/F for lenvatinib was then derived from the PK model. The data was collected and analyzed for lenvatinib plus pembrolizumab arm only.
Time frame: Cycle 1 Day 1: 0.5-10 hours post-dose; Cycle 1 Day 15: 0-12 hours post-dose; Cycle 2 Day 1: 0.5-10 hours post-dose (each cycle length=21 days)
Model Predicted Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted AUC for lenvatinib was then derived from the PK model. The data was collected and analyzed for lenvatinib plus pembrolizumab arm only.
Time frame: Cycle 1 Day 1: 0.5-10 hours post-dose; Cycle 1 Day 15: 0-12 hours post-dose; Cycle 2 Day 1: 0.5-10 hours post-dose (each cycle length=21 days)
Participants took part in the study at 167 investigative sites in Argentina, Australia, Brazil, Canada, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Mexico, New Zealand, Poland, Russia, Spain, Taiwan, Turkey, United Kingdom and the United States
| Milestone | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel |
|---|---|---|
| Started | 411 | 416 |
| Completed | 411 | 416 |
| Not completed | 0 | 0 |
PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression, as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.
| Months | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel |
|---|---|---|
| Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants | 6.6 ± 5.6 | 3.8 ± 3.6 |
PFS was defined as the time from the date of randomization to the date of the first documentation of disease progression, as determined by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death due to any cause (whichever occurred first). Disease progression was defined as at least 20 percent (%) increase (including an absolute increase of at least 5 millimeter \[mm\]) in the sum of diameter of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. PFS was estimated and analyzed using Kaplan-Meier method.
| Months | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| PFS Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on BICR in All-comer Participants | 7.2 ± 5.7 | 3.8 ± 3.6 |
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the date of data cut-off were censored at the date the participant was last known alive, or date of data cut-off, whichever occurred first.
| Months | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| Overall Survival (OS) in pMMR Participants | 18.0 (14.9 to 20.5) | 12.2 (11.0 to 14.1) |
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants who were lost to follow-up and those who were alive at the date of data cut-off were censored at the date the participant was last known alive, or date of data cut-off, whichever occurred first.
| Months | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| OS in All-comer Participants | 18.7 ± 15.6 | 11.9 ± 10.7 |
ORR was defined as the percentage of participants who had best overall response of either complete response (CR) or partial response (PR) as determined by BICR per RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| Percentage of participants | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| Objective Response Rate (ORR) in pMMR Participants | 30.3 ± 25.5 | 15.1 ± 11.5 |
ORR was defined as the percentage of participants who had best overall response of either complete response (CR) or partial response (PR) as determined by BICR per RECIST 1.1. CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| Percentage of Participants | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| ORR in All-comer Participants | 31.9 ± 27.4 | 14.7 ± 11.4 |
EORTC QLQ-C30 was a questionnaire which included 30 questions that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.
| Score on a scale | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in pMMR Participants | -6.80 ± -9.43 | -7.96 ± -10.86 |
EORTC QLQ-C30 was a questionnaire which included 30 questions that rates the overall quality of life in cancer participants. The first 28 questions use a 4-point scale (1=not at all to 4=very much) for evaluating function (physical, role, social, cognitive, emotional), symptoms (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea/vomiting, constipation, and pain) and financial difficulties. The last 2 questions use a 7-point scale (1=very poor to 7=excellent) to evaluate overall health and quality of life. Scores are transformed to a range of 0 to 100 using a standard EORTC algorithm. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/quality of life (QoL) represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problem.
| Score on a scale | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) in All-comer Participants | -5.97 ± -8.36 | -6.98 ± -9.63 |
TEAEs were AEs that occurred (or worsened, if present at baseline) after the first dose of study drug through 28 days after the last dose. An AE was any untoward medical occurrence in a participant temporally associated with use of study treatment, whether or not related to the treatment. An SAE was any untoward medical occurrence at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly/birth defect. An irAE was any unfavorable and unintended immune-related sign, symptom, or disease (new or worsening) temporally associated with study therapy, regardless of whether a causal relationship with the therapy could be determined.
| Participants | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| Number of Partricipants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Immune-Related Adverse Events (irAEs) | 237 | 121 |
TEAEs was defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to a TEAE in pMMR Participants | 140 | 42 |
TEAEs was defined as those AEs that occurred (or worsened, if present at Baseline) after the first dose of study drug through 30 days after the last dose of study drug. An AE was defined as any untoward medical occurrence in a participants or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Participants | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to a TEAE in All-comer Participants | 180 | 49 |
Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date a participant discontinued study treatment due to TEAEs.
| Months | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| Time to Treatment Failure Due to Toxicity in pMMR Participants | 429.6 ± 491.6 | 260.1 ± 356.2 |
Time to treatment failure due to toxicity was defined as the time from the date of randomization to the date a participant discontinued study treatment due to TEAEs.
| Months | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice(TPC):Doxorubicin or Paclitaxel |
|---|---|---|
| Time to Treatment Failure Due to Toxicity in All-comer Participants | 456.5 ± 520.6 | 259.7 ± 369.5 |
Pharmacokinetic (PK) samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted plasma concentration of lenvatinib was then derived from the PK model.
| nanograms per milliliter (ng/mL) | Lenvatinib 20 mg + Pembrolizumab 200 mg |
|---|---|
| Cycle 1 Day 1, 0.5-4h Post-dose | 152 ± 181 |
| Cycle 1 Day 1, 6-10 h Post-dose | 258 ± 124 |
| Cycle 1 Day 15, Pre-dose | 89.1 ± 69.6 |
| Cycle 1 Day 15, 2-12 h Post-dose | 310 ± 218 |
| Cycle 2 Day 1, Pre-dose | 67.2 ± 74.7 |
| Cycle 2 Day 1, 0.5-4h | 151 ± 155 |
| Cycle 2 Day 1, 6-10 h | 258 ± 138 |
PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted plasma concentration of lenvatinib was then derived from the PK model.
| ng/mL | Lenvatinib 20 mg + Pembrolizumab 200 mg |
|---|---|
| Cycle 1 Day 1, 0.5-4 h Post-dose | 140 ± 180 |
| Cycle 1 Day 1, 6-10 h Post-dose | 283 ± 136 |
| Cycle 1 Day 15, Pre-dose | 93.8 ± 61.4 |
| Cycle 1 Day 15, 2-12 h Post-dose | 335 ± 256 |
| Cycle 2 Day 1, Pre-dose | 67.9 ± 60.9 |
| Cycle 2 Day 1, 0.5-4 h | 153 ± 127 |
| Cycle 2 Day 1, 6-10 h | 278 ± 132 |
Sparse pharmacokinetic (PK) samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted CL/F for lenvatinib was then derived from the PK model. The data was collected and analyzed for lenvatinib plus pembrolizumab arm only.
| liter per hour (L/h) | Lenvatinib 20 mg + Pembrolizumab 200 mg |
|---|---|
| Model Predicted Apparent Total Clearance (CL/F) for Lenvatinib | 4.69 ± 1.39 |
Sparse PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted AUC for lenvatinib was then derived from the PK model. The data was collected and analyzed for lenvatinib plus pembrolizumab arm only.
| nanogram*hour per milliliter (ng*h/mL) | Lenvatinib 20 mg + Pembrolizumab 200 mg |
|---|---|
| Model Predicted Area Under the Plasma Drug Concentration-time Curve (AUC) for Lenvatinib | 4134 ± 1350 |
Collected over Up to approximately 79 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| First Course: Lenvatinib + Pembrolizumab | 317/406 (78.1%) | 237/406 (58.4%) | 404/406 (99.5%) |
| First Course: TPC Doxorubicin or Paclitaxel | 362/388 (93.3%) | 121/388 (31.2%) | 379/388 (97.7%) |
| Second Course: Lenvatinib + Pembrolizumab | 8/21 (38.1%) | 4/21 (19%) | 20/21 (95.2%) |
| TPC Crossover | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | First Course: Lenvatinib + Pembrolizumab | First Course: TPC Doxorubicin or Paclitaxel | Second Course: Lenvatinib + Pembrolizumab | TPC Crossover |
|---|---|---|---|---|
| Adrenal insufficiencyEndocrine disorders | 3/406 | 0/388 | 0/21 | 1/6 |
| PneumoniaInfections and infestations | 6/406 | 4/388 | 0/21 | 1/6 |
| MalaiseGeneral disorders | 0/406 | 0/388 | 0/21 | 1/6 |
| Renal disorderRenal and urinary disorders | 0/406 | 0/388 | 0/21 | 1/6 |
| ColitisGastrointestinal disorders | 7/406 | 1/388 | 1/21 | 0/6 |
| Decreased appetiteMetabolism and nutrition disorders | 9/406 | 0/388 | 1/21 | 0/6 |
| HyponatraemiaMetabolism and nutrition disorders | 2/406 | 2/388 | 1/21 | 0/6 |
| Ischaemic enteritisGastrointestinal disorders | 0/406 | 0/388 | 1/21 | 0/6 |
| General physical health deteriorationGeneral disorders | 3/406 | 1/388 | 1/21 | 0/6 |
| ArteriosclerosisVascular disorders | 0/406 | 0/388 | 1/21 | 0/6 |
| Event | First Course: Lenvatinib + Pembrolizumab | First Course: TPC Doxorubicin or Paclitaxel | Second Course: Lenvatinib + Pembrolizumab | TPC Crossover |
|---|---|---|---|---|
| HypothyroidismEndocrine disorders | 238/406 | 3/388 | 4/21 | 4/6 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 95/406 | 3/388 | 0/21 | 4/6 |
| HypertensionVascular disorders | 255/406 | 20/388 | 1/21 | 2/6 |
| DiarrhoeaGastrointestinal disorders | 223/406 | 76/388 | 4/21 | 3/6 |
| NauseaGastrointestinal disorders | 212/406 | 179/388 | 1/21 | 2/6 |
| VomitingGastrointestinal disorders | 149/406 | 80/388 | 2/21 | 3/6 |
| Weight decreasedInvestigations | 147/406 | 23/388 | 1/21 | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 184/406 | 83/388 | 4/21 | 3/6 |
| HypomagnesaemiaMetabolism and nutrition disorders | 80/406 | 27/388 | 2/21 | 3/6 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 55/406 | 22/388 | 1/21 | 3/6 |
The Intention-to-treat (ITT) population included all randomized participants.
| Age, Continuous(years) | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | Total |
|---|---|---|---|
| Mean | 63.2 ± 9.1 | 63.8 ± 9.2 | 63.5 ± 9.1 |
| Age, Customized(Participants) | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | Total |
|---|---|---|---|
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 206 | 204 | 410 |
| From 65-84 years | 205 | 210 | 415 |
| 85 years and over | 0 | 2 | 2 |
| Sex: Female, Male(Participants) | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | Total |
|---|---|---|---|
| Female | 411 | 416 | 827 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | Total |
|---|---|---|---|
| Hispanic or Latino | 59 | 73 | 132 |
| Not Hispanic or Latino | 309 | 288 | 597 |
| Unknown or Not Reported | 43 | 55 | 98 |
| Race (NIH/OMB)(Participants) | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 7 | 11 |
| Asian | 85 | 92 | 177 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 17 | 14 | 31 |
| White | 261 | 247 | 508 |
| More than one race | 7 | 13 | 20 |
| Unknown or Not Reported | 36 | 43 | 79 |
| Eastern Cooperative Oncology Group (ECOG) performance status(Participants) | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | Total |
|---|---|---|---|
| 0 = Fully active; no performance restrictions | 246 | 241 | 487 |
| 1 = Limited activity, ambulant, can-do light work | 165 | 175 | 340 |
| Prior history of pelvic radiation(Participants) | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | Total |
|---|---|---|---|
| Participants with pelvic radiation | 176 | 187 | 363 |
| Participants without pelvic radiation | 235 | 229 | 464 |
| Geographic region(Participants) | Lenvatinib 20 mg + Pembrolizumab 200 mg | Treatment of Physician's Choice (TPC): Doxorubicin or Paclitaxel | Total |
|---|---|---|---|
| Region 1 | 234 | 240 | 474 |
| Region 2 | 177 | 176 | 353 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 169 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2018 to primary completion in Mar 2022, 44 months.
Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's 44 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pembrolizumab · Lenvatinib